RCT: In non–critically ill hospitalized patients with COVID-19 | Critical Care & Emergencies

RCT: In non–critically ill hospitalized patients with COVID-19, the use of a P2Y12 Inhibitor (ticagrelor in 63% of patients and clopidogrel in 37%) in addition to a therapeutic dose of heparin did not improve survival free of organ support compared to therapeutic heparin alone.

https://www.linksmedicus.com/news/rct-non-critically-ill-hospitalized-patients-covid-19-use-p2y12-inhibitor-ticagrelor-63-patients-clopidogrel-37-addition-therapeutic-dose-heparin-d/